# Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)

> **NCT01801449** · PHASE2 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 6 (actual)

## Conditions studied

- DIRA

## Interventions

- **DRUG:** Rilonacept

## Key facts

- **NCT ID:** NCT01801449
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-12
- **Primary completion:** 2016-04-28
- **Final completion:** 2016-04-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01801449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01801449, "Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01801449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*